Viewing Study NCT04482894


Ignite Creation Date: 2025-12-25 @ 1:43 AM
Ignite Modification Date: 2025-12-27 @ 11:19 PM
Study NCT ID: NCT04482894
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-15
First Post: 2020-07-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
Sponsor: University of Virginia
Organization:

Study Overview

Official Title: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or High-Risk Myelodysplastic Syndrome: Randomized Phase II Study
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
Detailed Description: Participants in this study will be randomized to either an intervention group or a standard of care group. Participants in the intervention group will participate in regular visits with a palliative (or supportive) care specialist, while participants in the standard of care group will only see palliative care specialists if the clinician requests a referral. All participants will be asked to complete monthly questionnaires regarding their general well-being.

Participants have a greater chance of being assigned to the intervention group than to the standard of care group. On average, in every 5 people randomized, 3 will be randomized to the intervention and 2 will be randomized to standard of care.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: